多烯紫杉醇在乳腺癌患者体内的药代动力学研究  

Pharmacokinetics of docetaxel in breast cancer patients

作　　者：唐原君[1] 林晓燕[2] 余自成[1] 崔嵘嵘[2] 陈红君[1] 王芳[1] 

机构地区：[1]同济大学附属杨浦医院临床药学与药理学研究室,上海200090 [2]同济大学附属杨浦医院乳腺外科,上海200090

出　　处：《中南药学》2017年第6期765-768,共4页Central South Pharmacy

基　　金：上海市自然科学基金项目(编号:12ZR1429500)

摘　　要：目的研究多烯紫杉醇在乳腺癌患者体内的药代动力学。方法 10例乳腺癌患者采用多烯紫杉醇75 mg·m^(-2)静脉滴注1 h化疗,在化疗后不同时间采集血液标本,用HPLC法测定多烯紫杉醇血药浓度,用DAS 3.0软件计算药代动力学参数。结果多烯紫杉醇的血浆药物峰浓度Cmax均值为(3.345±1.05)mg·L^(-1),血药浓度-时间曲线下面积AUC0~12 h均值为(3.247±0.91)mg·h·L^(-1),消除半衰期t1/2均值为(9.602±3.72)h,清除率CL均值为(18.718±3.84)L/(h·m)-2。药动学参数在患者个体间存在较大差异。结论多烯紫杉醇在乳腺癌患者体内的药代动力学存在较大个体差异,提示在临床用药时需要监测多烯紫杉醇的血药浓度,进行个体化给药。Objective To determine the pharmacokinetics of docetaxel in Chinese adult breast cancer patients. Methods Ten breast cancer patients were intravenously administered at 75 mg ~ m-2 by a 1-hour infusion schedule, and plasma docetaxel concentrations were measured by high performance liquid chromatography at different time points in the chemotherapy. Pharmacokinetic parameters were calculated with DAS 3.0 software. Results The mean peak plasma concentration （Cmax） was （3.345±1.05） mg L-1, the mean area under con- centration-time curve （AUC0- 12h） was （3.247±0.91） mg h L-1, and the mean elimination half-life （t1/2） was （9.602± 3.72） h, the mean clearance was （18.718 ± 3.84） L h m-2. A large variability of pharmacokinetic parameters existed in these patients. Conclusion Due to the inter-individual variability of docetaxel pharmaco- kinetics, plasma docetaxel concentration should be monitored routinely after docetaxel administration in indi- vidual patient.

关 键 词：多烯紫杉醇 乳腺癌 药代动力学 

分 类 号：R94[医药卫生—药剂学] R96[医药卫生—药学]